ALBO has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALBO has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Albireo Pharma's adjusted earnings per share data for the three months ended in Sep. 2022 was $-1.920. Add all the adjusted EPS for the past 10 years together and divide 10 will get our e10, which is $-14.78 for the trailing ten years ended in Sep. 2022.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the E10 growth rate using E10 data.
As of today (2024-04-28), Albireo Pharma's current stock price is $44.15. Albireo Pharma's E10 for the quarter that ended in Sep. 2022 was $-14.78. Albireo Pharma's Shiller PE Ratio of today is .
The historical data trend for Albireo Pharma's E10 can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Albireo Pharma Annual Data | |||||||||||||||||||||
Trend | Sep12 | Sep13 | Sep14 | Sep15 | Sep16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | |||||||||||
E10 | Get a 7-Day Free Trial | -86.92 | -63.51 | -38.65 | -20.95 | -18.54 |
Albireo Pharma Quarterly Data | ||||||||||||||||||||
Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | |
E10 | Get a 7-Day Free Trial | -19.90 | -18.54 | -17.64 | -16.37 | -14.78 |
For the Biotechnology subindustry, Albireo Pharma's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Albireo Pharma's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Albireo Pharma's Shiller PE Ratio falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller P/E calculation. When we calculate the today's Shiller P/E ratio of a stock, we use today's price divided by E10.
What is E10? How do we calculate E10?
E10 is the average of the inflation adjusted earnings of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the E10 of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the earnings from 2001 through 2010.
We adjusted the earnings of 2001 earnings data with the total inflation from 2001 through 2010 to the equivalent earnings in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart earned $1 a share in 2001, then the 2001's equivalent earnings in 2010 is $1.4 a share. If Wal-Mart earns $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 earnings in 2010 is $1.35. So on and so forth, you get the equivalent earnings of past 10 years. Then you add them together and divided the sum by 10 to get E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Albireo Pharma's adjusted earnings per share data for the three months ended in Sep. 2022 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Sep. 2022 (Change) | * | Current CPI (Sep. 2022) |
= | -1.92 | / | 125.2265 | * | 125.2265 | |
= | -1.920 |
Current CPI (Sep. 2022) = 125.2265.
Albireo Pharma Quarterly Data
per share eps | CPI | Adj_EPS | |
201212 | -7.800 | 96.871 | -10.083 |
201303 | -11.100 | 98.209 | -14.154 |
201306 | -19.800 | 98.518 | -25.168 |
201309 | 1.500 | 98.790 | 1.901 |
201312 | -3.600 | 98.326 | -4.585 |
201403 | -8.700 | 99.695 | -10.928 |
201406 | -4.500 | 100.560 | -5.604 |
201409 | -3.000 | 100.428 | -3.741 |
201412 | -6.000 | 99.070 | -7.584 |
201503 | -5.400 | 99.621 | -6.788 |
201506 | -3.600 | 100.684 | -4.478 |
201509 | -1.560 | 100.392 | -1.946 |
201512 | -1.500 | 99.792 | -1.882 |
201603 | -2.700 | 100.470 | -3.365 |
201606 | -1.500 | 101.688 | -1.847 |
201609 | -0.750 | 101.861 | -0.922 |
201612 | -13.190 | 101.863 | -16.215 |
201703 | -1.060 | 102.862 | -1.290 |
201706 | -0.860 | 103.349 | -1.042 |
201709 | -0.730 | 104.136 | -0.878 |
201712 | -0.520 | 104.011 | -0.626 |
201803 | -0.150 | 105.290 | -0.178 |
201806 | -1.220 | 106.317 | -1.437 |
201809 | -1.170 | 106.507 | -1.376 |
201812 | -1.340 | 105.998 | -1.583 |
201903 | -1.390 | 107.251 | -1.623 |
201906 | -1.350 | 108.070 | -1.564 |
201909 | -1.730 | 108.329 | -2.000 |
201912 | -0.570 | 108.420 | -0.658 |
202003 | -2.230 | 108.902 | -2.564 |
202006 | -1.380 | 108.767 | -1.589 |
202009 | -1.960 | 109.815 | -2.235 |
202012 | -1.300 | 109.897 | -1.481 |
202103 | -2.290 | 111.754 | -2.566 |
202106 | -1.900 | 114.631 | -2.076 |
202109 | 2.900 | 115.734 | 3.138 |
202112 | -0.570 | 117.630 | -0.607 |
202203 | -2.190 | 121.301 | -2.261 |
202206 | -2.040 | 125.017 | -2.043 |
202209 | -1.920 | 125.227 | -1.920 |
Add all the adjusted EPS together and divide 10 will get our e10.
Albireo Pharma (NAS:ALBO) E10 Explanation
If a company grows much fast than inflation, E10 may underestimate the company's earnings power. Shiller PE Ratio can seem to be too high even the actual P/E is low.
For the Shiller P/E, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller P/E is also called PE10.
The Shiller P/E was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Be Aware
Shiller PE Ratio works better for cyclical companies. It gives you a better idea on the company's real earnings power.
Thank you for viewing the detailed overview of Albireo Pharma's E10 provided by GuruFocus.com. Please click on the following links to see related term pages.
Harford Simon N.r. | officer: CFO and Treasurer | AVON PRODUCTS, INC., 1345 AVENUE OF THE AMERICAS, NEW YORK NY 10105 |
Pamela Stephenson | officer: Chief Commercial Officer | C/O ZYNERBA PHARMACEUTICALS, INC., 80 W. LANCASTER AVENUE, SUITE 300, DEVON PA 19333 |
Martha J. Carter | officer: Chief Regulatory Officer | C/O AEGERION PHARMACEUTICALS, INC., 89 HEADQUARTERS PLAZA, SUITE 1212, MORRISTOWN NJ 07960 |
Jan Mattsson | officer: Chief Operating Officer | C/O ALBIREO PHARMA, INC., 50 MILK STREET, 16TH FLOOR, BOSTON MA 02109 |
Cooper Ronald Harold Wilfred | director, officer: President and CEO | C/O GENOCEA BIOSCIENCES, INC., 100 ACORN PARK DRIVE, 5TH FLOOR, CAMBRIDGE MA 02140 |
Michelle Graham | officer: Chief Human Resources Officer | 10000 WEHRLE DRIVE, CLARENCE NY 14031 |
Jason Duncan | officer: General Counsel | C/O ALBIREO PHARMA, INC., 10 POST OFFICE SQUARE, SUITE 502 SOUTH, BOSTON MA 02109 |
Paul Streck | officer: Chief Medical Officer | 10 FINDERNE AVENUE, BUILDING 10, BRIDGEWATER NJ 08807 |
Craig C. Hopkinson | director | 852 WINTER STREET, WALTHAM MA 02451 |
Perceptive Life Sciences Master Fund Ltd | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Susan Alesina | director | C/O ALBIREO PHARMA, INC., 53 STATE STREET, 19TH FLOOR, BOSTON MA 02109 |
Habib J Dable | director | C/O ACCELERON PHARMA INC., 128 SIDNEY STREET, CAMBRIDGE MA 02139 |
Patrick Taylor Horn | officer: Chief Medical Officer | C/O TETRAPHASE PHARMACEUTICALS, INC., 480 ARSENAL STREET, SUITE 110, WATERTOWN MA 02472 |
Perceptive Advisors Llc | 10 percent owner | 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
Joseph Edelman | 10 percent owner | C/O PERCEPTIVE ADVISORS LLC, 51 ASTOR PLACE, 10TH FLOOR, NEW YORK NY 10003 |
From GuruFocus
By Tiesvg Tiesvg • 12-20-2022
By Business Wire Business Wire • 01-24-2023
By Business Wire Business Wire • 01-11-2023
By Stock market mentor Stock market mentor • 02-08-2023
By PRNewswire PRNewswire • 01-31-2023
By PRNewswire PRNewswire • 01-23-2023
By Stock market mentor Stock market mentor • 02-03-2023
By sperokesalga sperokesalga • 02-14-2023
By PRNewswire PRNewswire • 01-28-2023
By Stock market mentor Stock market mentor • 02-02-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.